Guzman, ivermectin late treatment study: 19% lower mortality [p=0.35] https://c19p.org/guzman
copied to clipboard
Factors associated with increased mortality in critically ill COVID-19 patients in a Mexican public hospital: the other faces of health system oversaturation
et al., medRxiv, doi:10.1101/2021.03.04.21252084 (Preprint)
Retrospective 196 critically ill patients in Mexico. Patients overlap with the existing RCT by Beltran-Gonzalez (NCT04391127). This preprint shows a larger treated population and greater (non-statistically significant) improvement with ivermectin, RR 0.81 [0.53-1.24].
|
risk of death, 19.0% lower, HR 0.81, p = 0.35.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Guzman et al., 3/8/2021, retrospective, Mexico, North America, preprint, 11 authors, trial NCT04391127.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.